Science that started in the lab.

Research that couldn't stay in the lab.

For decades, the connection between the gut microbiome and the nervous system was well-understood in research circles — but almost entirely absent from women's health products. Dr. Jasenka Zubcevic, Dr. Manda Keller-Ross, and Dr. Sophie Darch had each spent years publishing research on exactly this connection, watching their findings sit in academic journals while millions of women struggled through perimenopause and menopause with inadequate options.

Panthea was founded with a simple premise: that the gut-brain axis is the missing mechanism in menopause care, and that women deserve a product built on original science rather than adapted from general wellness research. With $30M in federal funding already secured and a patent-pending probiotic strain, the team is now translating years of lab work into Panthea Core — launching Spring 2027.Monica Silvestre, who spent 20 years building global products at Canva, Yelp, and Pexels, joined as CEO to make sure the science reaches the women who need it — without losing its integrity in translation.

From idea to product

The patent-pending probiotic strain at the heart of Panthea Core wasn't designed in a product development meeting. It emerged from more than fifteen years of federally funded research, $30M in NIH grants, and 38 published papers. The clinical trial launching in 2026 was designed alongside the formulation from day one — not retrofitted after the fact.

Where we are today

Panthea is women-led by design, not by accident. Every co-founder, every key hire, every partnership decision has been made with one question in mind: does this serve the women we exist for? The 38-65 demographic navigating perimenopause and menopause has been underserved, underfunded, and underestimated by the health industry for too long. Panthea is not a supplement company that found a trend. It is a research team that refused to let their findings sit on a shelf.